Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes

Matilde Y Follo, Alessia De Stefano, Sara Mongiorgi, Irene Casalin, Alessandra Cappellini, Stefano Ratti, Andrea Pellagatti, Miriam Fogli, Michele Cavo, Lucia Manzoli, Lucio Cocco, Jacqueline Boultwood, Sarah Parisi, Stefania Paolini, Antonio Curti, Carlo Finelli

Blood (2022) 140 (Supplement 1): 6905–6906.

https://doi.org/10.1182/blood-2022-163628

Published: 2022

Journal Articles

Absolute Lymphocyte Count Is an Independent Survival Predictor in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

Gianluca Cristiano, Jacopo Nanni, Letizia Zannoni, Federico Zingarelli, Chiara Sartor, Sarah Parisi, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2022) 140 (Supplement 1): 11793–11794.

https://doi.org/10.1182/blood-2022-167035

Published: 2022

Journal Articles

Extracellular Vesicle-Based Liquid Biopsy Shows Clinical Relevance and Reveals Links with Single-Cell Metabolic Signature in Acute Myeloid Leukemia

Dorian Forte, Rafael J. Argüello, Roberto Maria Pellegrino, Husam B.R. Alabed, Martina Barone, Samantha Bruno, Francesco Fabbri, Ivan Vannini, Gianluca Cristiano, Sandra Buratta, Lorena Urbanelli, Carla Emiliani, Michele Cavo, Antonio Curti

Blood (2022) 140 (Supplement 1): 3389–3390.

https://doi.org/10.1182/blood-2022-165850

Published: 2022

Journal Articles

Parallel Detection of Single-Cells and Extracellular Vesicles from Bone Marrow and Peripheral Blood Reveals Asymmetric Immunometabolic Profile in Acute Myeloid Leukemia

Dorian Forte, Rafael J. Argüello, Martina Barone, Samantha Bruno, Gianluca Cristiano, Michele Cavo, Antonio Curti

Blood (2022) 140 (Supplement 1): 9158–9159.

https://doi.org/10.1182/blood-2022-166761

Published: 2022

Journal Articles

ATP-Dependent Induction of IDO1 Expression in Dendritic Cells Is Controlled through Non-Canonical NF-Kb Signaling Via P2Y11R and Leads to T Regulatory Cells Induction

Darina Ocadlikova, Letizia Vitali, Michele Cavo, Antonio Curti

Blood (2022) 140 (Supplement 1): 4522–4523.

https://doi.org/10.1182/blood-2022-160182

Published: 2022

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2022) 140 (Supplement 1): 6176–6178.

https://doi.org/10.1182/blood-2022-167334

Published: 2022

Journal Articles

Mesenchymal Stromal Cells Protect Acute Myeloid Leukemia Cells from Venetoclax-Induced Apoptosis through Contact-Dependent Mechanisms

Giulia Corradi, Samantha Bruno, Gaia Mazzocchetti, Jacopo Nanni, Andrea Polimeno, Michele Cavo, Marilena Ciciarello, Antonio Curti

Blood (2022) 140 (Supplement 1): 11424–11425.

https://doi.org/10.1182/blood-2022-166792

Published: 2022

Journal Articles

A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure

Chiara Sartor, Lorenzo Brunetti, Ernesta Audisio, Alessandro Cignetti, Letizia Zannoni, Gianluca Cristiano, Jacopo Nanni, Emanuela Ottaviani, Lorenza Bandini, Sarah Parisi, Stefania Paolini, Sofia Sciabolacci, Valeria Cardinali, Cristina Papayannidis, Michele Cavo, Maria Paola Martelli, Antonio Curti

Blood (2022) 140 (Supplement 1): 9034–9035.

https://doi.org/10.1182/blood-2022-165914

Published: 2022

Journal Articles

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Jorge E. Cortes, Pierre Fenaux, Karen Yee, Christian Recher, Andrew H. Wei, Pau Montesinos, David C Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Pierre Peterlin, Olga Polyanskaya, Jennifer Sweeney, Julie Brevard, Emma Barrett, Stephane De Botton

Blood (2022) 140 (Supplement 1): 6193–6196.

https://doi.org/10.1182/blood-2022-167330

Published: 2022

Journal Articles

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 145–149.

https://doi.org/10.1182/blood-2022-158030

Published: 2022

Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

Shukaib Arslan, Shaun Fleming, Nitin Jain, Giovanni Martinelli, Anthony S. Stein, James S. Blachly, Ashish Bajel, Antonio Curti, Giovanni Marconi, Giulia Fabbri, Yotvat Marmor, Shringi Sharma, Nairouz Elgeioushi, Natalia Couto-Francisco, Jamal Saeh, Raoul Tibes, Fathima Zumla Cader, Marina Konopleva

Blood (2022) 140 (Supplement 1): 9091–9093.

https://doi.org/10.1182/blood-2022-166192

Published: 2022

Journal Articles

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Blood (2021) 138 (Supplement 1): 216.

https://doi.org/10.1182/blood-2021-150958

Published: 2021

Journal Articles

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

Blood (2021) 138 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2021-149459

Published: 2021

Journal Articles

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Blood (2021) 138 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2021-147325

Published: 2021

Journal Articles

Circulating Extracellular Vesicles from Acute Myeloid Leukemia Patients Drive Distinct Metabolic Profile of Leukemic Cells and Reveal Crucial Lipidomic Biomarkers

Dorian Forte, Roberto Maria Pellegrino, Francesco Fabbri, Ivan Vannini, Samantha Bruno, Giulia Corradi, Rafael J. Argüello, Gianluca Cristiano, Sandra Buratta, Lorena Urbanelli, Carla Emiliani, Michele Cavo, Antonio Curti

Blood (2021) 138 (Supplement 1): 3471.

https://doi.org/10.1182/blood-2021-150339

Published: 2021

Journal Articles

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

Giovanni Marconi, Lorenza Bandini, Agnese Patuelli, Chiara Sartor, Sarah Parisi, Jacopo Nanni, Gianluca Cristiano, Letizia Zannoni, Giorgia Simonetti, Maria Teresa Bochicchio, Emanuela Ottaviani, Giovanni Martinelli, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2021) 138 (Supplement 1): 4446.

https://doi.org/10.1182/blood-2021-149450

Published: 2021

Journal Articles

An Outpatient Management for First Cycle of Venetoclax and Hypomethylating Agents Results in Reduced Infection Rate and Hospitalizations in Acute Myeloid Leukemia Patients

Jacopo Nanni, Cristina Papayannidis, Gianluca Cristiano, Giovanni Marconi, Chiara Sartor, Sarah Parisi, Rashed Saed, Letizia Zannoni, Emanuela Ottaviani, Lorenza Bandini, Nicoletta Testoni, Carmen Baldazzi, Paolo Ricci, Chiara Di Giovanni Bezzi, Rania Abd-alatif, Stefania Paolini, Michele Cavo, Antonio Curti

Blood (2021) 138 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2021-149535

Published: 2021

Journal Articles

Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy

Eytan M. Stein, Jörg Chromik, Cecilia Carpio, Rogier Mous, Jean-Jacques Kiladjian, Gheath Alatrash, Antonio Curti, Charles Craddock, Christoph Schmid, Robert Zeiser, Lamis K. Eldjerou, Hans-Jochen Jochen Weber, Claire Fabre, Jeffrey Scott, Daniel J. DeAngelo

Blood (2021) 138 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2021-149751

Published: 2021

Journal Articles

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 698.

https://doi.org/10.1182/blood-2021-144905

Published: 2021

Journal Articles

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 4440.

https://doi.org/10.1182/blood-2021-146585

Published: 2021

NARROW

Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes

Absolute Lymphocyte Count Is an Independent Survival Predictor in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

Extracellular Vesicle-Based Liquid Biopsy Shows Clinical Relevance and Reveals Links with Single-Cell Metabolic Signature in Acute Myeloid Leukemia

Parallel Detection of Single-Cells and Extracellular Vesicles from Bone Marrow and Peripheral Blood Reveals Asymmetric Immunometabolic Profile in Acute Myeloid Leukemia

ATP-Dependent Induction of IDO1 Expression in Dendritic Cells Is Controlled through Non-Canonical NF-Kb Signaling Via P2Y11R and Leads to T Regulatory Cells Induction

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Mesenchymal Stromal Cells Protect Acute Myeloid Leukemia Cells from Venetoclax-Induced Apoptosis through Contact-Dependent Mechanisms

A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure

Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Circulating Extracellular Vesicles from Acute Myeloid Leukemia Patients Drive Distinct Metabolic Profile of Leukemic Cells and Reveal Crucial Lipidomic Biomarkers

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

An Outpatient Management for First Cycle of Venetoclax and Hypomethylating Agents Results in Reduced Infection Rate and Hospitalizations in Acute Myeloid Leukemia Patients

Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only